Isosorbide Dinitrate And Hydralazine Hydrochloride Tablet, Film Coated
Product Images NDC 73141-012

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Isosorbide Dinitrate And Hydralazine Hydrochloride (NDC 73141-012). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A2a Integrated Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Figure1)

A Kaplan-Meier survival plot showing time to death by all causes in Black patients, comparing treatment with isosorbide dinitrate and hydralazine hydrochloride tablets versus placebo over approximately 600 days. The graph illustrates a higher survival percentage with the active treatment, indicating a 43% reduction in mortality. A Log-Rank Test reports a P value of 0.012.*

FDA Label Image

Figure2 (Figure2)

Kaplan-Meier plot depicting time to first hospitalization for heart failure in Black patients treated with isosorbide dinitrate and hydralazine hydrochloride tablets versus placebo. The graph shows percent without hospitalization over time (days) up to 600 days, highlighting a 39% risk reduction in hospitalization for the active treatment group. The plot includes patient numbers at risk over time for each group and statistical significance (P < 0.001, Log-Rank Test).*

FDA Label Image

Figure3 (Figure3)

A bar chart titled 'Change in Minnesota Living With Heart Failure Score' comparing isosorbide dinitrate and hydralazine hydrochloride tablets versus placebo over 18 months. The y-axis shows change in the score with improvement downward. Bars show greater improvement for active tablets compared to placebo at multiple time points with significance indicated (P <0.05 and P <0.01). Sample sizes decrease over time, ending with 512 for active and 528 for placebo at the endpoint.*

FDA Label Image

Figure4 (Figure4)

A figure showing results for demographic, baseline medication, and clinical characteristic subgroups in Black patients from a study of isosorbide dinitrate and hydralazine hydrochloride tablets. It presents two forest plots comparing all-cause mortality and first hospitalization for heart failure, with relative risk and 95% confidence intervals for each subgroup, indicating whether outcomes favor the medication or placebo.*

FDA Label Image

Hcl (Hcl)

Chemical structure of hydralazine hydrochloride, showing the molecular arrangement including hydrazine and aromatic rings associated with the compound.*

FDA Label Image

Isdn-180label (Isdn 180label)

Label for Isosorbide Dinitrate and Hydralazine HCl Tablets 20 mg/37.5 mg, oral film-coated tablets. The package contains 180 tablets. Distributed by A2A Integrated Pharmaceuticals, Bowling Green, KY. Storage instructions specify room temperature (15°C - 30°C). The label includes a barcode and NDC 73141-012-18.*

FDA Label Image

Isdn-90label (Isdn 90label)

Label for Isosorbide Dinitrate and Hydralazine HCl Tablets, 20 mg/37.5 mg, film-coated tablets. The package contains 90 tablets, distributed by A2A Integrated Pharmaceuticals in Bowling Green, KY. The label includes storage instructions and a barcode.*

FDA Label Image

Isdn (Isdn)

Chemical structure of isosorbide dinitrate, showing its molecular arrangement with nitrate groups attached to a bicyclic ring system.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.